This study looks at the effectiveness of the chemotherapy drugs Everolimus and Sunitinib, used in sequence, in treating people with advanced renal cell carcinoma. Trial details: Participants will all receive the same treatment. This involves six-weekly cycles comprising four weeks of sunitinib 50 mg once daily followed by two weeks rest The second cycle comprises five weeks of everolimus 10 mg once daily followed by one weeks rest. The study aims to see the effectiveness of treatment by looking at survival and disease progression in patients after six months.